<!DOCTYPE html>
<html lang="en">
<head>        <meta charset="utf-8">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">    <link
        rel="stylesheet"
        href="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/css/bootstrap.min.css"
        integrity="sha384-Gn5384xqQ1aoWXA+058RXPxPg6fy4IWvTNh0E263XmFcJlSAwiGgFAW/dAiS6JXm"
        crossorigin="anonymous"
    />
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/c3/0.6.12/c3.min.css"/>
    <style>
        h2 {
            margin-top: 35px;
        }

        html, body {
            height: 100%;
        }

        body {
            display: flex;
            flex-flow: column;
        }

        .footer {
            margin-top: auto;
            padding-top: 1em;
            background-color: #f5f5f5;
        }
    </style>    <title>SALVADOR_MARTIN_PEDIATRIC_TBD_ANTI_TNF_THERAPY_NONRESPONDER_POST_TREATMENT_UP</title></head>

<body>
<nav class="navbar navbar-expand-lg navbar-light bg-light">
    <span class="navbar-brand">
        Molecular Signatures Database
    </span>
</nav>

<div class="container" style="margin-top: 50px; margin-bottom: 50px">
<div class="card">
        <div class="card-header">
            SALVADOR_MARTIN_PEDIATRIC_TBD_ANTI_TNF_THERAPY_NONRESPONDER_POST_TREATMENT_UP
        </div>
        <div class="card-body">
                <p>Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. Methods: An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged &lt; 18 years who started treatment with infliximab or adalimumab (29 responders and nine non-responders). Whole gene expression profiles from total RNA isolated from whole blood samples of six responders and six non-responders taken before administration of the biologic and after two weeks of therapy were analyzed using next-generation RNA sequencing. The expression of six selected genes was measured for purposes of validation in all of the 38 patients recruited using qPCR. Results: Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) &gt;0.6 or &lt;_0.6 and p value &lt; 0.05). After validation, FCGR1A, FCGR1B, and GBP1 were overexpressed in non-responders two weeks after initiation of anti-TNF treatment (Log2FC 1.05, 1.21, and 1.08, respectively, p value &lt; 0.05). Conclusion: Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD.</p>
            <dl>
                <dt>Local Unique Identifier</dt>
                <dd><a href="https://bioregistry.io/msigdb:M41741">M41741</a>
                </dd>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            in taxon (<code>RO:0002162</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/NCBITaxon:9606">NCBITaxon:9606</a></li>
                        </ol>
                    </dt>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            has part (<code>BFO:0000051</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/ncbigene:5920">ncbigene:5920</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:79651">ncbigene:79651</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:79713">ncbigene:79713</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:23780">ncbigene:23780</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:1890">ncbigene:1890</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3553">ncbigene:3553</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:552891">ncbigene:552891</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3001">ncbigene:3001</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3659">ncbigene:3659</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3107">ncbigene:3107</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3136">ncbigene:3136</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:80830">ncbigene:80830</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:10170">ncbigene:10170</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:9246">ncbigene:9246</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:440836">ncbigene:440836</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:2634">ncbigene:2634</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:6398">ncbigene:6398</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:100132417">ncbigene:100132417</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:710">ncbigene:710</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:9172">ncbigene:9172</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:2633">ncbigene:2633</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:118932">ncbigene:118932</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:2210">ncbigene:2210</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:2209">ncbigene:2209</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:116071">ncbigene:116071</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:115362">ncbigene:115362</a></li>
                        </ol>
                    </dt>
            </dl>
            <span class="badge badge-warning">Term generation via PyOBO is currently under construction</span>
            <blockquote>
                Term(reference=Reference(prefix=&#39;msigdb&#39;, identifier=&#39;M41741&#39;, name=&#39;SALVADOR_MARTIN_PEDIATRIC_TBD_ANTI_TNF_THERAPY_NONRESPONDER_POST_TREATMENT_UP&#39;), definition=&#39;Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. Methods: An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged &lt; 18 years who started treatment with infliximab or adalimumab (29 responders and nine non-responders). Whole gene expression profiles from total RNA isolated from whole blood samples of six responders and six non-responders taken before administration of the biologic and after two weeks of therapy were analyzed using next-generation RNA sequencing. The expression of six selected genes was measured for purposes of validation in all of the 38 patients recruited using qPCR. Results: Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) &gt;0.6 or &lt;_0.6 and p value &lt; 0.05). After validation, FCGR1A, FCGR1B, and GBP1 were overexpressed in non-responders two weeks after initiation of anti-TNF treatment (Log2FC 1.05, 1.21, and 1.08, respectively, p value &lt; 0.05). Conclusion: Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD.&#39;, provenance=[Reference(prefix=&#39;pubmed&#39;, identifier=&#39;33429950&#39;, name=None)], relationships=defaultdict(&lt;class &#39;list&#39;&gt;, {TypeDef(reference=Reference(prefix=&#39;RO&#39;, identifier=&#39;0002162&#39;, name=&#39;in taxon&#39;), comment=None, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=None, holds_over_chain=None): [Reference(prefix=&#39;NCBITaxon&#39;, identifier=&#39;9606&#39;, name=&#39;Homo sapiens&#39;)], TypeDef(reference=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000051&#39;, name=&#39;has part&#39;), comment=&#39;Inverse of part_of&#39;, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000050&#39;, name=&#39;part of&#39;), holds_over_chain=None): [Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;5920&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;79651&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;79713&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;23780&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;1890&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3553&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;552891&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3001&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3659&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3107&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3136&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;80830&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;10170&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;9246&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;440836&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;2634&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;6398&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;100132417&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;710&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;9172&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;2633&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;118932&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;2210&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;2209&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;116071&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;115362&#39;, name=None)]}), properties=defaultdict(&lt;class &#39;list&#39;&gt;, {&#39;category_code&#39;: [&#39;C2&#39;], &#39;sub_category_code&#39;: [&#39;CGP&#39;], &#39;contributor&#39;: [&#39;Anthony Castanza&#39;], &#39;exact_source&#39;: [&#39;Table 4. List of genes expressed differentially between responders (R) and non-responders (NR) after two weeks of anti-TNF treatment.&#39;], &#39;external_details_url&#39;: [&#39;https://www.mdpi.com/1999-4923/13/1/77/htm&#39;]}), parents=[], synonyms=[], xrefs=[], alt_ids=[], namespace=None, is_obsolete=False)
            </blockquote>
        </div>
    </div></div>

<footer class="footer">
    <p class="small text-center text-muted">
        Generated with PyOBO
    </p>
</footer>

<script src="https://code.jquery.com/jquery-3.2.1.slim.min.js"
        integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN"
        crossorigin="anonymous"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/js/bootstrap.min.js"
        integrity="sha384-JZR6Spejh4U02d8jOt6vLEHfe/JQGiRRSQQxSfFWpi1MquVdAyjUar5+76PVCmYl"
        crossorigin="anonymous"></script></body>
</html>